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Simon (42) and Susan (40) have had several failed treatment cycles with donor sperm. 
They had always assumed that Simon’s diagnosis of a low sperm count was the only factor 
limiting their fertility. As a result of treatment taking several years, Susan has also been 
diagnosed with infertility due to poor ovarian response. She was advised that is has 
become very unlikely that she will conceive using her own oocytes. The couple is now 
considering oocyte donation in combination with ICSI. As oocyte donation is prohibited in 
their home country, they have to travel abroad. In addition, they only find very limited 
information and are uncertain which country and which clinic to travel to. They feel 
confused by the infinite amount of information they find online and have the impression 
that much of this information is unreliable. At the same time, they feel time is pressing, and 
they want to continue treatment as soon as possible and hopefully finally conceive.  
 
Traveling to another country for medical and for fertility treatment is not a new 
phenomenon. For centuries, couples have traveled to places considered conducive to 
infertility such as spas, fertility shrines and specific landmarks in the hope that these 
will have a positive impact on their fertility. The development of in vitro fertilization 
(IVF) has brought hope to many experiencing infertility and, together with quick and 
affordable international travel, has provided the momentum for cross border 
reproductive services (CBRS). Those experiencing fertility problems who faced limited 
access to, or availability of, appropriate services in their own countries started to 
consider travel abroad to access services that they hoped would realize their family-
building aspirations. Although IVF and related procedures have become available 
quickly in many developed and developing countries, various factors have contributed 
to individuals and couples travelling for treatment. Key amongst these are:  
  law evasion in jurisdictions with restrictive legislation (e.g. prohibition of oocyte 
donation in Italy and Germany; prohibition of sperm donation in jurisdictions 
subject to Sharia law; prohibition of either commercial or altruistic surrogacy in 
many jurisdictions);   lengthy waiting lists for, or unavailability of, specific services (e.g. oocyte 
donation in the United Kingdom, sperm donation for couples in a same-sex 
relationship or single women in several jurisdictions);   the wish to undergo fertility treatment without the knowledge of family or 
friends;   the wish to undergo treatment in the individualǯs or coupleǯs country of origin; 
and   beliefs that treatment in another country may be more successful and/or less 
costly.  
 
As a consequence, although accurate and robust data are not available, the number of 
individuals and couples engaging in CBRS is believed to have risen significantly over the 
last 20 years. [1-3] According to a pilot study carried out by ESHRE (European Society of 
Human Reproduction and Embryology), 24,000 to 30,000 treatment cycles alone were 
provided annually to foreign patients in the following six destination countries: Belgium, 
the Czech Republic, Denmark, Slovenia, Spain and Switzerland. [4] Patients had travelled 
from forty-nine different ǲhomeǳ countries, with approximately two thirds of patients 
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coming from Italy (31.8%), Germany (14.4%), the Netherlands (12.1%) and France 
(8.7%). It is not surprising that country-specific associations were observed. The 
majority of Italians traveled to Switzerland and Spain, most Germans to the Czech 
Republic, most Dutch and French patients travelled to Belgium and – to a lesser extent – 
Spain. The nature of these flows can be explained largely by the relatively easy access 
provided by shared national borders. French, Norwegian and Swedish patients were the 
most likely to travel for sperm donation, while Denmark, Belgium and Switzerland were 
the most popular destinations for sperm donation. Patients from Germany and the UK 
were the most likely to travel for oocyte donation, and Spain and the Czech Republic 
were the most popular destination countries for both oocyte and embryo donation. 
Extrapolating the data relevant for Germany, we can assume that approximately 2000 
German couples travel annually mainly for egg donation. [See Table 1 for a listing of patientǯs home countries and the destination country for treatment.] Survey data from 
the United States indicate that 4% of all fertility treatments (around 6,000 cycles p.a.) is 
provided for non-US domiciliaries [12,13]. The largest groups of incoming patients are 
from Latin America (39%) - as with the European findings, geographical proximity 
contributing to a significant extent - and Europe (25%). By contrast, the incidence of 
patients from the US traveling abroad for care is estimated to be far lower than the rate 
of incoming patients [6,12]. 
On an international level, Blyth et al. [14] have shown that:  patients travel from more or less anywhere to everywhere, although not all 
destination countries have a reputation for high-quality service provision;  a number of countries are both home and destination countries; and  although, in general, patients report a relatively high level of satisfaction with the 
services they have received, clinical experience also suggests that some clinics 
leave questions unanswered. For example, there can be little transparency 
regarding recruitment strategies and financial compensation for donors and 
surrogates, and counseling is seldom available. In addition, treatment contracts 
may be minimal and only cover issues relevant for the clinic. 
 
While not all CBRS arrangements give major cause for concern, those that are potentially 
most problematic remain under-researched. There is emerging evidence of potentially 
serious risks to patients, donors, surrogates and children such as high numbers of 
multiples, unknown quality of medical services for donors and surrogates, and offspringsǯ lack of access to their gamete or embryo donor or surrogate. [see, for 
example, 3, 15]. Furthermore, there has been criticism regarding the dearth of available 
information. Despite the growth of the CBRS industry, there is only minimal 
international monitoring and little is known of the services provided by, and 
remuneration of, intermediary agencies.   These organizations symbolize the interface of 
medicine and business in this field and the internet has become a ǲvirtual siteǳ of CBRS activities. Utilizing CBRS to evade domestic restrictions and/or to restrict other peopleǯs 
knowledge of recourse to assistance with family-building, in turn, promotes secrecy. 
This ensures that many of the practices relating to CBRS remain ǲhiddenǳ, with 
significant potential psychosocial, ethical and legal consequences [16]. However, the 
secrecy has also impacted on the uptake of counseling. CBRS is only beginning to emerge 
as a theme for infertility counseling and little has been published by experts in this field, 
with the German Society for Fertility Counselling being the only organization that has 
developed CBRS guidelines for counselors. [17] 
  
Lack of a framework for CBRS 
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Due to different and sometimes contradictory cultural and ethical values, the 
harmonization of legislation between different jurisdictions is unlikely to occur. It has 
also been argued that harmonization may not be desirable as it denies ethical, cultural 
and religious pluralism. Thus, ǲharmonizationǳ may actually result in ǲuniformizationǳ and CBRS could be considered a ǲsafety valveǳ that helps to avoid conflicts. [18] On the 
other hand, the current situation lends itself to the exploitation of vulnerable parties, 
above all, the donors, surrogates and children born from these services. Their voices so 
far have not been heard to any significant degree. Furthermore, with the exception of a 
small British study relating to the impact of overseas multiple-embryo transfer during 
single IVF cycles  [15] no research has been conducted on or with children born as a 
result of CBRS, especially on the psychosocial impact of their mixed cultural/ethnic 
background. Last but not least, worries have been expressed that CBRS could create 
demands and burdens on both the home and the destination countries. [15]  
 
These concerns have led to the development of practice guidelines by two professional 
bodies, ES(RE  and ASRM respectively. ES(REǯs ǲGood practice guide for cross border reproductive care for centers and practitionersǳ [19] and the ASRM Ethics Committeeǯs ǲopinionǳ [20] are both welcomed for making a start in acknowledging the challenges as 
well as the opportunities presented by CBRS. However, the scope of both documents as 
regards infertility counseling practice is modest. The ESHRE guidelines identify the need 
of foreign patients to receive the same level of medical care; information, counseling and 
psychosocial support as are provided for domestic patients; the need to minimize health 
risks for donors and surrogates; and the possibility of professional collaboration in 
those countries where this does not pose a legal problem. It fails to acknowledge the 
problematic areas: the interests of donors or surrogates, or the possibility of children 
born as a result of treatment to access information about them.  
  
The committee opinion of the Ethics Committee of the American Society for 
Reproductive Medicine (20) summarises what is currently known about the incidence 
of, and the key reasons for utilizing CBRS.  It describes the potential benefits of travel to 
access fertility services and acknowledges the potential harms of CBRS, It focuses only 
on the responsibilities of physicians; there is no mention of the roles of counselors. 
Physicians in departure countries are not considered to have any duty to be informed 
about or disclose risks and benefits of treatment elsewhere and physicians in 
destination countries are seen to have a duty to deliver the same quality of care required 
for all domestic patients. The ASRM does not consider that the physician is obliged ǲto discuss the patientǯs circumvention tourismǲ. 
 
In order to expand on these existing practice guides, minimum standards of care have 
been proposed [21] that could be implemented on a voluntary basis by clinics, 
professionals and research institutions, and thus provide a degree of transparency to 
other professionals as well as to potential patients, donors and surrogates. Most 
importantly, they could contribute to national and pan-national discussion of the 
challenges in CBRS. These minimum standards cover the following issues: 
 
1. Voluntary commitment to the standards to be followed as well as voluntary 
oversight by a national or supra-national body. This is especially pertinent for 
those countries that have not yet established legislation. 
2. A commitment to altruistic donation and surrogacy and a ban on commercial 
procedures. It is difficult to say the least to determine a just price for services 
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such as donation or surrogacy. There should be national and pan-national discussions regarding financial compensation in order to agree on a ǲjustǳ price. 
3. Gamete donors and surrogates should receive the same level of care as recipients. 
They should be provided with full healthcare coverage to enable them to access 
free medical treatment required after potential complications and they should be 
insured for any (long-term) health impairment resulting from the donation or 
surrogate service. 
4. Since donors and surrogates undergo health risks for the benefit of others, a high 
level of informed consent should be ensured. They should receive comprehensive 
and accurate information regarding the medical procedure and the psychosocial 
implications in an unbiased manner. This should also include legal information 
such as the status of the donor/surrogate, her husband (in the case of a married 
surrogate or female donor) and the recipients/intended parents. An independent 
ombudsman or a donor/surrogate advocate can be established to represent the 
interests of these parties. 
5. All parties involved should have access to psychosocial counseling prior to, 
during and post treatment. Psychological assessment may be necessary in some 
cases, but this should neither be confused with, nor substituted for, counseling.  
6. In complex cases, prior to new and/or innovative treatment, multi-disciplinary 
ethics committees installed in the clinic providing treatment should be involved.  
7. In order to avoid conflicts of interest, the recruitment of donors and surrogates 
should be carried out independently from those institutions that are responsible 
for the informed consent procedure, the psychosocial counseling and the legal 
advice. 
8. There has been a lot of controversy regarding the anonymity and ability to 
identify donors and surrogates. From a moral perspective, offspring should be 
granted as much autonomy as possible, including the possibility of accessing full 
information about their biological and genetic origins, if they so wish to do so. 
Therefore, clinics should document records for a minimum of 80 years and 
offspring should be entitled to access this information. As a complementary 
requirement, donors should be able to learn about the outcome of their donation 
and the number of offspring conceived with their gametes, if they wish. Registers 
should also enable contact between half-siblings, if mutually agreed upon. 
9. All countries should strive towards self-sufficiency as regards ART services so as 
to reduce the need for patients to travel. Donors and surrogates do not need to 
provide their service to recipients from abroad (usually with a higher living 
standard) in order to generate income. In accordance with national cultural and 
ethical principles, ARTs should be regulated so that this aim is achieved.  
10. There are a number of international regulations and conventions on human 
rights such as the Convention of Human Rights and Biomedicine of the Council of 
Europe [22], the Convention for the Protection of Human Rights and 
Fundamental Freedoms [23], the Ethical Issues in Obstetrics and Gynecology [24] 
or the International Alliance of Patientsǯ Organisations ȋ)APOȌ – Declaration on 
Patient-Centered Healthcare [25] that can serve as a framework for CBRS. 
 
While adherence to such minimum standards can contribute towards more ethical and 
respectful treatment, considerable challenges lie in the way of their acceptance. 
However, they can form the basis of discussion and collaboration between different 
professional groups, and between professionals in different countries, to ensure that 
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patients, donors, surrogates and the children born as a result of CBRS are not exposed to 
unnecessary risks. 
 
Counseling in Cross Border Reproductive Services 
The provision of appropriate counseling as an integral part of fertility services has been 
well documented [for an overview see 26-28] and qualification guidelines have been 
issued by several organizations. [29] There is agreement that professionals offering 
fertility counseling should: 
1. hold a graduate level qualification in a psychosocial profession; 
2. hold a relevant professional license to practice; 
3. demonstrate relevant training in the medical and psychosocial aspects of 
infertility; 
4. demonstrate a minimum level of relevant clinical experience; and, 
5. demonstrate engagement in continuing professional education. 
 
When counseling in CBRS, additional requirements arise for professionals. These 
include: knowledge and information regarding the legislation of typical destination 
countries; awareness of societal attitudes and their impact on patients; attentiveness for 
ethical issues, such as commodification, and the potential of exploitation of donors and 
surrogates, and its effect on patients; as well as being able to raise these issues with 
patients.  
 
Given that counseling is non-directive, supports the decision-making process of patients, 
and explores the implications of family building options rather than recommends 
specific treatments, counseling does not direct patients towards treatments that may 
not be allowed in their home country. Whether counseling in this area may entail 
punitive consequences, however, is dependent upon national legislation and/or case 
law. Fertility counselors, therefore, need to be informed about the implications of 
relevant legislation and proceed with care, even though supra-national bodies such as 
ESHRE [30] endorse evasion of domestic law by medical professional as in the interest 
of patient autonomy by providing information on treatment options abroad.  
 
Fertility counselors also need to explore their personal and professional attitude 
regarding CBRS, especially regarding treatment options that are controversial in their 
country and that raise moral dilemmas. There is a risk of exploiting donors and 
surrogates, especially when CBRS takes place between countries with very different 
living standards and customs (e.g. North America and Europe on the one hand, and 
Eastern Europe and South East Asia on the other). Counselors need to explore their 
professional attitude towards such challenging issues, beware of transference issues and 
make use of professional supervision to clarify these. Patients deserve understanding 
and respect for their family building plans. This does not imply that counselors should 
refrain from raising controversial issues. In fact, it is often a relief for patients to be able 
to explore these in a supportive and empathetic environment, and counseling often 
affords the only possibility to provide time and space for this. The counseling process, 
however, should not be influenced by the attitude of the fertility counselor. 
 
The case presented at the beginning illustrates many common matters presented in 
CBRS counseling: patients pursuing treatment that is not available in their home 
country, dealing with limited information, resources and a sense of time pressure.  The 
following section will further examine these clinical issues and provide case vignettes 
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when working with (a) patients, (b) donors and surrogates and (c) the resulting 
children. [17] Given that CBRS is a relatively new phenomenon, there is little research 
on which these issues can be based. Therefore, counseling interventions are based on 
existing knowledge in the area of fertility counseling, especially third party 
reproduction, although the focus will be on issues that are relevant where treatment takes place outside the patientsǯ country of residence. For specific counseling in third 
party reproduction, reference should be made to the relevant chapters in this book.  
 
Preparing for CBRS 
Fertility counselors should respect the reproductive autonomy of all parties involved, 
including the interest of offspring created, resulting in a well-considered and measured 
use of reproductive medicine. Counseling should be accessible prior to, during and after 
fertility treatment in a language that patients can use to explore emotional issues; 
counseling in the country of residence is most likely to fulfill these conditions. Providing 
counseling prior to treatment may mitigate the risk of accepting treatment that could 
entail physical or psychological risks for patients or the future child. However, clinical 
experience indicates that many patients take up counseling after failed treatment cycles, 
and in the area of CBRS, after having decided on a clinic and thus the country of 
treatment. 
 
Susan and Richard sought counseling after they had signed a contract with a clinic and 
had already made payments towards their first treatment cycle. During the counseling 
sessions, they raised their frustration regarding the lack of communication by the clinic. 
Their emails remained unanswered, the responsible staff could not be reached by telephone 
and they were unable to clarify several issues in the treatment protocol they did not 
understand. This could not be rectified by counseling. We focused one session on this 
frustrating situation and this helped the couple develop a greater understanding of the 
gullibility their emotional situation had resulted in when signing the contract. They 
developed more confidence and were able to proceed with much more assertiveness during 
medical treatment. 
 
From a counseling perspective, this is frustrating from several perspectives. This 
situation is indicative of the importance of pre-treatment counseling. Although fertility 
counselors are not in a position to recommend specific clinics, even though there may be 
no adverse legal consequences for doing so where the treatment planned is possible in the ǲhomeǳ country, we firmly believe that patients who have considered their needs prior to medical treatment and have developed their personal ǲcheck-listǳ for the clinics 
they consult, are more likely to choose a clinic that fulfills their needs. In the case of CBRS, this ǲcheck-listǳ includes issues such as reliable communication via email or 
telephone and the possibility of contacting staff in emergency situations. This is one of 
the tasks of counseling before treatment: preparing patients for what lies ahead of them 
and supporting them to make informed choices. 
  
Exploring infertility always includes a critical appraisal of limits in life, limits of medical 
treatment, and limits of emotional suffering. It, therefore, may also result in patients 
deciding against pursuing treatment abroad, in which case counseling focuses on 
developing strategies for a life without children.  
 
As many patients who intend to undertake treatment abroad have already experienced 
treatment failure in their home country, fertility counselors should explore whether 
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they have sufficient psychological, emotional and financial resources to continue 
treatment, and whether this is feasible given their physical, psychological and emotional 
health. Furthermore, treatment abroad can be associated with moral qualms, especially 
if the treatment intended is prohibited in the patientsǯ home country. Careful 
exploration is necessary in order to assess whether the patients are sufficiently 
confident to proceed. Moral doubts can also result in keeping the treatment a secret 
from family members and friends and thus, vital emotional and practical support may be 
absent during treatment. In some cases, time off treatment may be indicated to work 
through and resolve some of these issues; in others, patients may decide not to proceed 
with treatment altogether. For those who proceed, fertility counseling should include 
the exploration of general issues, issues related to the use of their own gametes and 
issues related to third party reproduction. 
 
Treatment Issues 
Patients need to ensure that they fully understand the information regarding the 
treatment planned and counselors should advise patients of the importance of being as 
fully informed as possible before they embark on overseas treatment. Patients who are 
not sufficiently proficient in the language of destination countries, or where competence 
in a common language with service providers is limited, may often struggle to 
understand details. If a translation and/or interpretation service is required, patients 
should ensure – as well as they can – that the translation is correct. They should resist 
any pressure to sign consent forms they do not fully understand. Patients can request 
clinics to provide treatment plans, consent forms and contract drafts prior to their first 
visit. This gives them the opportunity to read them through and make arrangements for 
independent translation, if necessary. They should also ensure that there are no medical 
counter-indications against the treatment planned and that there are adequate success 
rates.  
 
In order to facilitate the flow of necessary information, clinics in both home and 
destination countries should be provided with relevant medical records which patients 
may have to facilitate on their own. In some countries, there are restrictions, such as 
oocyte donation can only be carried out for medical reasons, and clinics need to have 
documentation confirming this. Medical documents may also be important in case of 
complications or malpractice. Patients, however, should be aware that it may be difficult 
to take effective legal action in the case of medical malpractice in a destination country, 
especially where no protective regulation or legislation is in place.  
 
Under certain conditions, patient health insurance may reimburse costs for treatment 
abroad. This is dependent upon the legal status of the treatment and upon the state or 
the individual insurance policy. Patients should be encouraged to clarify any available 
reimbursement prior to treatment. Clinics should provide a transparent and legally 
binding treatment plan, which also details the cost (including the compensation or 
payment for donors and surrogates, if applicable). Couples should be aware that several 
treatment cycles may be necessary to achieve pregnancy and that carrying out 
treatment abroad also entails traveling, accommodation and incidental costs (such as 
visas, for example). For costs during pregnancy and for birth, the country of conception 
is irrelevant; reimbursement is dependent upon the parentǯs/parentsǯ health insurance 
scheme. 
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Patients may be more willing to risk multiples after having experienced recurrent 
treatment failure in their home country. Although the high number of multiples 
following CBRS has been criticized [15, 31], and recent European data indicate that the 
general rate of multiple pregnancy is decreasing within Europe, there are significant 
national differences, with four and more embryos regularly transferred in several 
countries (e.g. Bulgaria, Lithuania, Moldova, Romania and Serbia) [32]. Similar practices 
may be prevalent in other countries, especially in the absence of formal policies or 
guidelines restricting the number of embryos that may be transferred in a single IVF 
cycle. [31]. For example, one American study found that at least half of the clinicians 
surveyed would deviate from ASRM embryo transfer number guidelines in certain 
situations (33) 
 
Couples should be made aware of this risk whenever more than one embryo is 
transferred or hormonal induction is used to stimulate the growth of oocytes, and be 
informed that current guidelines seek to minimize the risk of multiples by only 
transferring one or two embryos. [31,34, 35]  
 
 
After five failed IVF cycles, Steven and Joyce, both in their mid-thirties, were very frustrated 
as the clinic would only transfer two embryos per treatment cycle in order to minimize the 
risk of multiples. They had contacted a clinic abroad that offered to transfer a higher 
number of embryos with the promise of a higher pregnancy rate. As their financial 
resources were such that they could afford only one more cycle, they contemplated having 
four embryos transferred, hoping to increase their chances of conceiving.  
 
It is easy for the fertility counselor to develop empathy for couples who have had to experience so many ǲmini lossesǳ as couples often described failed treatment. The couplesǯ desire to ǲput all their eggs into one basketǳ ȋpun intendedȌ is also understandable. At the same time, the counselorǯs emotional distance allows a greater 
degree of reflection and enables him/her to understand the risks of transferring three or 
more embryos to such a relatively young woman. The issues here are two-fold: to use 
professional knowledge in a way that helps clients to make informed decisions and to 
appreciate that the information of transferring a certain number of embryos was given 
by medical doctors who tend to be afforded a higher professional status than mental 
health professionals.  
 
One way of avoiding a professional power struggle (for oneself as well as for patients 
who would find them in between two professional views) is to focus on the psychosocial 
issues. Fertility counselors can and should inform couples like Steven and Joyce of the 
medical and physical consequences of multiple pregnancies.   Focus should be on 
questions regarding the scope of social support typically required after multiples are 
born, the realistic options of both partners to share child care, and equally important, 
the financial burden multiples can result in.  
 
Counseling prior to treatment using the patients’ own gametes 
Many patients travel in the hope that less restrictive legislation will enable medical 
practitioners to offer different or innovative treatment that may result in higher 
pregnancy rates. Such treatment can include PGD or blastocyst transfer with selected 
embryo transfer. Others travel in the hope that treatment is less costly outside their 
country of residence. Patients considering traveling abroad should be informed that it is 
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vital that treatment adheres to international standards and they should satisfy 
themselves regarding the standards of care available; caution is advised if independent 
confirmation of standards is not readily available. Should innovative treatment be 
offered, patients should be adequately informed about the implications, including the 
financial cost, as well as any risks this treatment may entail for themselves or the 
resulting child. This requires fertility counselors to continuously stay up-to-date with 
medical and scientific developments. 
 
Counseling prior to third party reproduction 
Patients need to be knowledgeable of the legal regulations, guidelines or common 
practice regarding anonymity or identifiability of the donor. In many countries, 
legislation mandates anonymity [31] and patients are given little or no non-identifiable 
information about their donor(s). Clinical experience indicates that at the time of 
treatment, for several reasons, many patients pay little attention to legal regulations. 
They are unaware of legislation, they naively follow recommendations of their previous 
clinic, or their desire is focused on the short-term need to conceive and have a child 
rather than on long-term issues relevant for the child.  
 
Once the child is born and parents consider disclosure, however, having undergone 
treatment in a country where donors or surrogates remain anonymous may result in a 
dilemma: parents can disclose the use of a donor or surrogate, but the child will not be 
able to access any information about his/her biological background. Furthermore, in 
many countries, it may be legally possible for clinics to provide non-identifiable 
information, although they are reluctant to do so. It is important for fertility counselors 
to explore with patients their intentions regarding disclosure and draw attention to the 
need for selecting a country and a clinic that provides the future child with the 
possibility to access information about the donor or surrogate, should he/she wish so.  
 
Counseling should also explore the values and attitudes of patients regarding the 
circumstances of the donor(s) and/or surrogate(s). Whether the donation was altruistic 
and/or an autonomous decision or the result of a financial need, the fact that gamete 
donors and surrogates are typically young and healthy men and women, who take 
medical risks for the benefit of others, usually are considerations that impact on the patientsǯ moral assessment. Although these issues cannot be resolved, in many cases, 
counseling is the only opportunity that provides time and space to raise them: 
 
After cancer of the uterus and a hysterectomy, Julie and Ben were confident that surrogacy 
was a positive choice for them to have children. They had explored clinics in several 
countries and were unable to decide which clinic and country to choose. They struggled 
most with what they called ǲbelly-buyingǳ, the concept that, as a couple from a developed 
country in a comfortable financial situation, they were able to ǲbuyǳ the ǲbellyǳ of a woman 
who would use this payment for life necessities. The agencies they had contacted described 
their payment as ǲa wonderful gift to the surrogate and her familyǳ and failed to 
acknowledge couple’s different perspective. Although the issue of payment could not be 
resolved in counseling, it was a relief for Julie and Ben to have time and space to explore 
their feelings and their moral concerns. 
  Surrogacy arrangements may be most challenging for counselorsǯ ethical values. )n these 
situations, typically young women make available their body and risk the potential side 
effects of ART treatment, pregnancy and birth. Whereas historically, these were women 
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often known to the patients who had altruistic motives, nowadays, commercial agencies 
around the globe are involved, collaborating with clinics and legal advisors. In many, if 
not most cases, we can assume that the costs paid to the professionals involved are 
higher than the compensation or payment the surrogate receives. In some countries, 
there is contact between the surrogate and the intended parents, which allows intended 
parents to show their gratitude and appreciation beyond the financial transaction that 
takes place. In others, such contact is banned. Our experience shows that intended 
parents can struggle with the concept of payment to donors and surrogates. They find it 
difficult, if not impossible, to ǲfix a priceǳ for oocytes, semen or pregnancy. )f this 
exchange is anonymous, they also struggle with the concept that they cannot show any appreciation for this ǲgift of lifeǳ.  Some have written a letter to donors and surrogates in 
which they describe their experiences and gratitude and hoped that the clinics passed 
them on.  
 
In some cases, these issues only become relevant to patients once pregnancy has been 
established and having a child becomes a reality. In other cases, they become acute after 
the child is born or starts to ask questions about her/his conception. It is therefore 
important for counseling to be available at every stage of treatment and after the child is born, to be available in the parentsǯ home country, and for parents to be informed about 
further resources, such as support organizations. 
 
Although fertility counselors are not in a position to provide binding legal advice, they 
should raise the legal implications of gamete and embryo donation, and surrogacy. The 
legal implications of international surrogacy are very complex, and intended parents 
should ensure that they have all the relevant information relating to the country of 
treatment. In most jurisdictions, the woman giving birth is the legal mother and her 
husband or partner, the legal father. Consequently, the intended parents, even if their 
gametes were used, are not the legal parents. Intended parents, who are single or in a 
same sex relationship, should be informed about the legal status of the donor in relation 
to the child. In cases where there is no male partner to automatically assume legal 
paternity, in some jurisdictions the donor may both run the risk of assuming parental 
obligations and be able to claim visitations rights. Fertility counselors should encourage 
legal consultation in these situations. 
 
Regardless of their genetic relationship to the child, intending parents may need to 
apply to adopt him/her or take other available legal measures to ensure a transfer of 
parentage from the surrogate to themselves [36]. In some jurisdictions, transfer of legal 
parentage is stipulated in legally enforceable contracts prior to treatment (See chapter 
9), although in most jurisdictions such contracts are not legally enforceable. 
 
In some international surrogacy arrangements there have been disputes about the 
nationality of the child [14], especially in those cases where surrogacy is prohibited in the intended parentsǯ country of residence, and embassies have been reluctant to issue 
birth certificates, passports, or other legal documents which are required for the intending parentsǯ to return home with the child [37]. It is therefore vital for intended 
parents to be knowledgeable about the documents they need in the country of 
treatment, the documents they need in order to travel home with the baby and those 
required for the legal proceedings in their home country to transfer parentage. 
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It is also advisable for intended parents not to rely on the legal information provided by 
the clinic or the agency, but to seek independent advice from a legal expert experienced 
in this area. The legal information should also entail details about the documents 
regarding donors and surrogates, such as what information is recorded, how long and 
where these records are kept. Countries belonging to the European Union, for example, 
must keep documents for a minimum of 30 years. [38] However, there is currently no 
evidence that this document retention period is adhered to in all EU member countries. 
The right of offspring to access these documents is subject to national legislation. 
Intended parents should also be informed that these records may be relevant beyond 
the 30-year period and that it may be necessary in the case of medical complications to 
have access to the identity of the donor or the surrogate. 
 
Counseling donors and surrogates 
In many destination countries, there is no evidence that counseling is available for 
donors and surrogates. Therefore, in addition to the general counseling interventions for 
donors and surrogates described in Chapters  8 and 9, fertility counselors need to raise 
issues specific to CBRS. These include issues, such as the question whether donors are 
aware of, and have consented to, the use of their oocytes or their semen for recipients 
from other countries; in this case, their future children will have half-siblings living in 
other countries. There is little international agreement regarding the number of 
offspring per semen donor, [39] and there is no international agreement regarding the 
number of offspring per oocyte donor, let alone the maximum number of treatment 
cycles to which she should be subjected. In those jurisdictions where there are no legal 
limits, donors should be informed about national guidelines applicable to them and be 
encouraged to determine the number of offspring they wish to contribute to. Similarly, 
surrogates should be informed about relevant national guidelines regarding the 
maximum number of embryos to be transferred (in order to minimize the risk of 
multiples for surrogates and any consequent multifetal reduction) and of pregnancies 
or, if there are no guidelines, be encouraged to determine themselves the number of 
pregnancies they are willing to carry out for others.  
 
The meaning of financial compensation or payment should be carefully explored in 
order to assess financial coercion. Although this is especially pertinent in developing and 
emerging countries such as India and Thailand, it is also relevant in countries such as 
Spain, the Czech Republic or the USA where donors and surrogates typically are young 
women with (considerably) less financial resources than patients. [40] Last but not 
least, more research is required on the short and long-term implications for donors and 
surrogates. There is a dearth of information on how these groups fare with their 
decision in later life and what their needs are regarding information about and contact 
to offspring they have helped to conceive. 
 
Counseling offspring 
The psychosocial needs of offspring conceived via donated gametes, embryos, and via 
surrogacy in a foreign country is another issue the fertility counselor should address 
with intended parents, ideally prior to treatment [41]; these are covered in detail in 
chapter 18. For offspring conceived abroad, there may be additional issues such as 
exploring the meanings of have a dual cultural/ethnic background. In inter-country 
adoption, racial, ethnic and cultural awareness have been found to be essential 
ingredients for successful identity formation [42]. Currently, there is little evidence 
either from formal research or from clinical practice that this issue is considered at all 
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by those providing services for individuals and couples traveling for treatment. It is 
highly likely, however, that similar issues will apply to offspring following CBRS whose 
parents may be of different races of cultures.  More research is also required for this 
group, especially if conceived via CBRS, in order to understand both the short and long 
term needs of these children. 
 
Counseling Resources 
 
Information on legislation and international guidelines  
As the policy situation in many countries is dynamic and many countries do not have 
legislation pertaining to ART or to specific aspects of ART such as the establishment of 
legal parenthood following[43] surrogacy, the number of offspring a donor can help to 
conceive or the right of offspring to access biological information, it will be difficult for 
counselors to stay abreast of these developments. An overview has been put together by 
ESHRE (http://www.eshre.eu/Guidelines-and-Legal/Legal-documentation.aspx and 
http://www.eshre.eu/Guidelines-and-Legal/Legislation-for-MAR-treatments.aspx), the website ǲBiopolicywikiǳ ȋwww.biopolicywiki.org) and the German Max-Plank Institute 
for International Penal Law (http://www.mpicc.de/meddb/show_all.php, only available 
in German).  
 
Patient organizations 
It can be helpful to refer to patient organizations in the country of treatment where they 
exist. These are generally knowledgeable not only in the legal area but can also provide 
information regarding the medical practice in their country. In addition, they can help to 
establish contact to other patients in their country to provide support. The international 
umbrella organization iCSi (International Consumer Support for Infertility; 
www.icsicommunity.orgȌ and the European organization ǲFertility Europeǳ 
(www.fertilityeurope.eu) have compiled a list of national patient organizations. 
 
Fertility counseling organizations 
In several countries, specialist fertility counseling organizations have been founded. 
These can provide information for counselors regarding national legislation, guidelines 
and practices and also provide a list of counselors that can be contacted by patients. The 
international umbrella organization IICO (International Infertility Counseling 
Organization - http://www.iico-infertilitycounseling.org/about-us/iico-members) 
provides links to national organizations. 
 
Guidelines for counseling in the area of CBRS 
The German Fertility Counselling Organisation has published guidelines for counseling 
in the area of CBRS. These guidelines have also been published in English (17). In 
addition, Table 2 provides questions for fertility counselors to consider regarding 
counseling issues occurring in the context of CBRS. 
 
Reflections of the Authors 
 
PT: I think all infertility counselors worldwide have seen tremendous changes in our 
field in recent years. Working in Germany, it is fascinating to see how many couples 
travel in order to obtain treatment, mainly oocyte donation, which is prohibited in 
Germany. Whereas 6 or 7 years ago, I hardly did any counseling in this area, I now 
usually have several clients every week. These counseling sessions can pose challenges, 
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for both the clients and myself. Many German couples are considering treatment in 
Spain, which is considered to be the hub for oocyte donation in Europe. This is also the 
country suggested by many medical professionals. From a psychosocial perspective, 
however, treatment in Spain cannot be recommended. Legislation is such that all donors 
remain anonymous and children born as a result from third party treatment in Spain 
will not be able to access their biological origins. In a sense, this is a déjà-vu situation: 
Many years ago, there were controversial discussions regarding sperm donor anonymity 
in Germany. This is now – to a large degree – resolved and offspring are able to access 
the identity of the donor. Now, we are having very similar discussions with patients 
considering treatment in Spain (and any other country that grants anonymity to donors 
and/or surrogates). Often, couples know very little about the legal implications and are 
not aware of the rights and possibilities of their future children. Often, too, the needs of 
their children are so far in the future that they are not taken into consideration before or during treatment. The couplesǯ focus is on getting pregnant and it can be a challenge to 
raise long-term implications that do not affect them, but their future child. Given the 
legal situation in Germany, counselors are also concerned about potential legal issues if 
they counsel in an area that is prohibited; they fear criminal penalties. At the same time, 
there is little discussion about counseling issues in this area and thus little awareness. 
This is the reason why, as chair of the German Society for Fertility Counselling , I have 
been involved in issuing guidelines for counseling in third party reproduction as well as 
for counseling individuals and couples traveling for treatment. Both guidelines provide 
psychosocial professionals with background of the international scientific discussion in 
this area and describe issues relevant for counseling in these areas.  
 
As fertility counselors, we work in a dynamic area, both technically and ethically. We 
have seen and will continue to see many changes, both in the way infertility is treated 
and regarding the groups that access medical treatment. I am certain that the future will 
hold new challenges for us – and I hope that we will continue professional development 
and exchange so that our role in the provision of treatment will continue to grow. 
 
 
EDB: It is now almost a decade since I first commented on what was then generally referred to as ǲreproductive tourismǲ (44) . This paper has now become a routinely- 
cited work in this field (89 citations according to Google Scholar as of March 31 2014). 
Over that time I have also undertaken further research, commentary and professional 
practice (3, 12, 14, 45-48).  What has become apparent over this period is both 
increased professional and academic interest in the field and increased media interest in 
the more exotic/problematic examples of cross border reproductive travel.  The effect of 
this appears to be increasing awareness of both the opportunities and the hazards 
associated with cross border reproductive travel and realization of the need to ensure 
the effective protection of the interests of patients, donors, surrogates, the children to be 
born as a result of the procedures undertaken, as well as and any existing children that 
the patients,  donors or surrogates may already have. It is gratifying to have been able to 
contribute to policy developments in this area (20), a report that incidentally credits me with drawing attention to unscrupulous ǲbait and switchǲ practices. ) did, indeed, refer 
to the plight of some parents and their children once the children started to grow up and 
it was evident from the childrenǯs physical characteristics that a different donor had 
been used to the one stated by the clinics. I wish I had also been sufficiently inventive to come up wth the ǲbait and catchǲ phrase. Unfortunately ) didnǯt! 
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Table 1: CBRS: Home and Destination Countries (compiled by the authors based on 
data from recent studies [3-11] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Home 
country 
Destination country Service 
Australia Thailand Sex selection 
Canada USA Donor oocytes 
Denmark Baltic States, Czech 
Republic, Greece, 
Russia, Span,  
Donor oocytes 
Egypt Spain, other European 
countries 
Donor oocytes 
   
France Belgium Donor Sperm 
Germany Spain, Czech Republic Donor oocytes 
Hungary USA Surrogacy 
India Europe, USA, United 
Arab Emirates 
Standard IVF 
India Thailand, USA Sex selection 
Israel Romania Donor oocytes 
Italy Austria, Belgium, Czech 
Republic, Greece, 
Slovenia, Spain, 
Switzerland, UK 
Donor oocytes, donor 
sperm, embryo 
cryopreservation, PGD 
Japan USA All services 
Macedonia Belgium ICSI-TESE 
Macedonia Czech Republic Donor oocytes  
Middle East Jordan Sex selection 
Netherlands Belgium Donor sperm 
Norway Denmark Donor sperm 
Portugal Russia, Spain Donor oocytes 
Sweden Denmark Donor sperm 
Sweden Baltic States, Finland, 
Russia 
Donor oocytes 
Switzerland Austria Standard IVF 
Switzerland Eastern Europe, Spain Donor oocytes 
UK Czech Republic, Spain Donor oocytes 
USA India Surrogacy 
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Table 2. Questions for fertility counselors to consider on counseling issues arising 
in the context of CBRS  What do I know about the implications of legislation relevant to me when 
providing counseling to patients who travel for treatment, especially those who 
intend treatment prohibited in my country of practice?   What type of legal and medical information can I provide as a psychosocial 
professional? Are there any restriction/limitations by professional bodies or by 
legislation? (Typically, counselors can provide basic medical and legal 
information but are not in a situation to provide binding information.)  What is my attitude towards treatment prohibited or not offered in my country? 
Do I think patients have a right to exert their reproductive autonomy even if they 
engage in an activity that is illegal if carried out at home? Does my attitude vary 
according to the type of treatment; if yes, can I describe why?  How do I feel about women who undergo invasive procedures for the sake of 
others (oocyte donors, surrogates)?  How do I feel about these groups receiving financial compensation/payment for 
these procedures? Should there be a lower and/or upper limit for such payment? 
What or who should determine the amount of this payment?  How do I feel about the need or right of offspring conceived by third party 
reproduction to access information about the donor and/or surrogate? 
How do I feel if this is possible in my country, but not the treatment country of 
patients (or vice versa)? 
 
 
